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Abstract
Background: Current knowledge on the exact ligand causing expression of TREM-1 on neutrophils and monocytes
is limited. The present study aimed at the role of underlying infection and of the causative pathogen in the
expression of TREM-1 in sepsis.
Methods: Peripheral venous blood was sampled from 125 patients with sepsis and 88 with severe sepsis/septic
shock. The causative pathogen was isolated in 91 patients. Patients were suffering from acute pyelonephritis,
community-acquired pneumonia (CAP), intra-abdominal infections (IAIs), primary bacteremia and ventilator-
associated pneumonia or hospital-acquired pneumonia (VAP/HAP). Blood monocytes and neutrophils were isolated.
Flow cytometry was used to estimate the TREM-1 expression from septic patients.
Results: Within patients bearing intrabdominal infections, expression of TREM-1 was significantly lower on
neutrophils and on monocytes at severe sepsis/shock than at sepsis. That was also the case for severe sepsis/shock
developed in the field of VAP/HAP. Among patients who suffered infections by Gram-negative community-
acquired pathogens or among patients who suffered polymicrobial infections, expression of TREM-1 on monocytes
was significantly lower at the stage of severe sepsis/shock than at the stage of sepsis.
Conclusions: Decrease of the expression of TREM-1 on the membrane of monocytes and neutrophils upon
transition from sepsis to severe sepsis/septic shock depends on the underlying type of infection and the causative
pathogen.
Background
Septic syndrome is one of the leading causes of death.
Its great lethality had led to several randomized trials of
the administration of various types of immunotherapy.
The concept of all these types of therapeutic approach
was to modulate the exaggerated immune response of
the host [1]. However most of results were
disappointing. Several probable explanations for these
failures have been given; among them the heterogeneity
of patients is the most likely. This probably has to do
with the type of underlying infection, the causative
microorganism and the co-morbid conditions. In a
recent prospective study of the Hellenic Sepsis Study
Group http://www.sepsis.gr 505 patients were enrolled;
changes of the innate and adaptive immunity were eval-
uated with immunophenotyping performed within the
first 24 hours from diagnosis. Results showed that
changes occurring during transition from sepsis to
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type of underlying infection [2].
Triggering receptor expressed on myeloid cells -1
(TREM-1) is a pattern-recognition receptor expressed
on neutrophils and monocytes. It participates in innate
immune responses and it is activated in the event of dis-
seminated bacterial infections like sepsis. Expression of
TREM-1 is up-regulated after stimulation with bacterial
and fungal products. This leads to production of pro-
inflammatory mediators, mainly of tumour necrosis fac-
tor-alpha and of interleukin-8. Although the exact ligand
of TREM-1 remains unknown, it is believed that micro-
bial molecules like endotoxins of the cell wall of Gram-
negative bacteria and peptidoglycan of the cell wall of
Gram-positive cocci may stimulate TREM-1 [3-9]. Miss-
ing identification of the exact ligand for TREM-1 creates
the hypothesis that TREM-1 expression on neutrophils
and monocytes in sepsis may differ according to the
type of infection causing sepsis and/or the type of impli-
cated bacteria.
Based on recent data for the crucial role of the type of
the underlying infection in immune responses in sepsis
[2], the purpose of the present study was to investigate
the pattern of TREM-1 expression on cells of myeloid
origin in a prospective cohort of sepsis in relation with
the causative infection and the offending pathogen.
Methods
Study design
This is a prospective, multicentre clinical study con-
ducted over the period June 2009-December 2009. None
of the patients was enrolled in the studies already con-
ducted and published by the Hellenic Sepsis Study
Group [2,10,11]. The protocol was approved by the
Ethics committees of all hospitals of the participating
study sites. Written consent was provided from patients
or their first-degree relatives for patients unable to
consent.
Inclusion criteria were: a) age ≥ 18 years; b) sepsis due
to either lower respiratory tract infection or acute pyelo-
nephritis or intrabdominal infection or primary bactere-
mia/fungemia; and c) blood sampling within less than
24 hours from advent of signs of sepsis.
Exclusion criteria were: a) HIV infection and b) neu-
tropenia defined as an absolute neutrophil count lower
than 1000 neutrophils/mm
3.
Patients were classified as uncomplicated sepsis and as
severe sepsis and/or septic shock according to the cri-
teria of the ACCP/SCCM [11,12].
Acute infection of the lower respiratory tract was
defined by all the following [13]: (1) physical signs com-
patible with a lower respiratory tract infection; and b)
new pulmonary infiltrates on chest x-ray. It was divided
into community-acquired pneumonia (CAP) if the
patient had no history of contact with any hospital
environment within the last 3 months; and hospital-
acquired pneumonia (HAP) if either the patient had
some contact with hospital environment within the last
3 months or infection was diagnosed more than 48
hours after hospital admission without being under
incubation upon admission.
Ventilator-associated pneumonia (VAP) was HAP pre-
sented when a patient under intratracheal intubation
and mechanical ventilation for ≥ 48 hours had all the
following [14,15]: a) core temperature > 38°C or < 36°C;
b) purulent tracheobronchial secretions; and c) new pul-
monary infiltrates on chest x-ray.
Acute pyelonephritis was defined for every patient
with all the following [16]: a) core temperature > 38°C;
b) radiological evidence consistent with the diagnosis;
and c) ≥ 10 white blood cells in centrifuged urine sam-
ple or ≥ 2 + in urine stick for white blood cells and
nitrite.
Acute intra-abdominal infection was defined for every
patient with all the following [17] a) core temperature >
38°C; and b) radiological evidence (abdominal x-ray,
abdominal ultrasound, abdominal or computed tomo-
graphy) consistent with an acute abdominal infection.
Primary bacteremia or fungemia was defined for any
patient with all the following [17]: a) peripheral blood
culture positive for Gram-positive or Gram-negative
bacteria or fungal species. Coagulase-negative Staphylo-
coccus spp and skin commensals were considered con-
taminants unless isolated at least two times or isolated
from both a peripheral vein and a central catheter and
they had the same antibiograms; and b) absence of any
primary site of infection after extensive patient work-
out.
Patients’ follow up
Seven ml of blood were sampled after venipuncture of
one forearm vein under aseptic conditions; five ml were
collected into a heparin-coated tube for flow cytometry;
another two ml were collected into pyrogen-free tubes.
T u b e sw e r et r a n s p o r t e dw i t h i no n eh o u rv i aac o u r i e r
service to the central lab located at the 4
th Department
of Internal Medicine, ATTIKON General Hospital.
Enrolled patients were followed-up on a daily basis for
a total of 28 days. APACHE II scores were calculated
upon enrolment.
Flow cytometry
Red blood cells were lysed with ammonium chloride 1.0
mM. White blood cells were washed three times with
PBS (pH. 7.2) (Merck, Darmstadt, Germany) and stained
with the monoclonal antibody anti-TREM-1(R&D Sys-
tems, Minneapolis, USA) at the fluorochrome phycoery-
thrin (PE, emission 575 nm). The incubation took place
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0.5 ml phosphate buffered saline pH: 7.2 cells were ana-
lyzed through the EPICS XL/MSL flow cytometer (Beck-
man Coulter Co, Miami, FL, USA) with gating for
neutrophils and monocytes based on their characteristic
forward and side scattering. IgG isotypic negative con-
trols PE conjugated (IgG1) were applied before the start
of analysis. Results were expressed as % of gated cells
and as mean fluorescence intensity (MFI).
sTREM-1 measurements
Pyrogen-free tubes were centrifuged and serum was kept
refrigerated at -70°C until assayed. Concentrations of
soluble TREM-1 (sTREM-1) were measured in duplicate
by an enzyme immunoassay (R&D Inc, Minneapolis,
USA). The lower detection limit was 15.1 pg/ml.
Statistical analysis
Results were expressed as means ± SE. Comparisons of
baseline qualitative characteristics were done by X
2-test
and of quantitative baseline characteristics by the Stu-
dent’s t-test. Comparisons of TREM-1 expression
between patients at sepsis and patients at severe sepsis/
shock with the same type of infection or pathogen were
done by the Kruskall-Wallis test; those between different
types of infections or pathogens separately for patients
at sepsis and patients at severe sepsis/shock were done
by the Mann-Whitney U test. Correlation between
APACHE II score and TREM-1 expression was done
according to Spearman’s rank of order. P values below
0.05 after adjustment for multiple comparisons were
considered significant.
Results
A total of 213 patients were enrolled in the study; 125
with sepsis and 88 with severe sepsis/shock. Their
demographic and clinical characteristics are shown in
Table 1. As expected, APACHE II scores and mortal-
ity were greater among patients with severe sepsis/
shock.
Expression of TREM-1 on the membrane of neutro-
phils and monocytes of the first day of patients with
sepsis and severe sepsis/shock are shown in Figure 1.
Among patients with intra-abdominal infection, expres-
sion of TREM -1 on neutrophils and monocytes, was
significantly lower at severe sepsis/shock compared with
sepsis (P = 0.009 for neutrophils, P = 0.022 for mono-
cytes). That was also the case for TREM-1 expression
Table 1 Demographic and clinical characteristics of patients enrolled in the study.
Sepsis Severe sepsis/shock p
Number 125 88
Male/Female 69/56 43/45 0.307
Age (years, mean ± SD) 62.5 ± 22.2 72.5 ± 13.1 < 0.0001
APACHE II score 11.52 ± 5.76 22.68 ± 8.50 < 0.0001
Type of infection (n) p: 0.004
Acute pyelonephritis 56 18
Pneumonia (CAP) 16 20
Intra-abdominal Infection 30 20
Bacteremia 13 15
VAP/HAP 10 15
Predisposing Factors (n, %) 0.188
Chronic Renal Disease 15 (12.0) 12 (13.6)
Chronic Obstructive Pulmonary Disease 10 (8.0) 10 (11.4)
Heart Failure 9 (7.2) 17 (19.3)
Diabetes mellitus type 2 27 (21.6) 17 (19.3)
Solid tumor malignancy 5 (4.0) 7 (7.9)
Isolated pathogens irrespective of source (n, %) 0.037
Escherichia coli 21 (16.8) 4 (4.5)
Pseudomonas aeruginosa 7 (5.6) 5 (5.7)
Klebsiella pneumoniae 5 (4) 9 (10.2)
Acinetobacter baumannii 2 (1.6) 7 (7.9)
Other Gram-negatives 10 (8.0) 4 (4.5)
Staphylococcus aureus 2 (1.6) 2 (2.3)
Other Gram-positive 2 (1.6) 2 (2.3)
Death 10 (8.0) 49 (55.7) < 0.0001
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0.049 between severe sepsis/shock and sepsis).
When comparing patients at severe sepsis with
patients at septic shock, it was found that expression of
TREM-1 on neutrophils was further decreased in the
event of septic shock within patients with intrabdominal
infection (P = 0.049 compared with severe sepsis) and
within patients with VAP/HAP (P = 0.009 compared
with severe sepsis).
No significant correlation was found between expres-
sion of TREM-1 on neutrophils and monocytes and
APACHE II score.
Gram-negative community-acquired bacteria were the
most frequent isolated pathogens. Expression of TREM-
1 on neutrophils of patients infected by the latter type
of pathogens was significantly lower in severe sepsis/
shock than in sepsis (P = 0.030) (Figure 2). No differ-
ences were found between severe sepsis and septic
shock. When analysis involved only patients with sepsis,
the MFI of TREM-1 on neutrophils of patients bearing
infections by community-acquired Gram-negative bac-
teria was lower than the MFI of TREM-1 on neutrophils
of patients bearing infections by hospital-acquired
Gram-negative bacteria (P = 0.003 between them).
Among the total patients where the causative patho-
gen was isolated, septic syndrome was of monomicro-
bial origin in 78 patients; in 20 patients septic
syndrome was of polymicrobial origin. MFI of TREM-1
on the membrane of monocytes of patients bearing
infections of monomicrobial origin at severe sepsis/
shock was greater than of patients with infections of
polymicrobial origin at severe sepsis/shock (P = 0.032)
(Figure 3). No differences were found between severe
sepsis and septic shock. However, analysis of the
expression of TREM-1 within patients with sepsis
found that it was significantly greater in patients with
polymicrobial infections than in patients with monomi-
crobial infections (P = 0.040 regarding differences of %
Figure 1 Expression of TREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock on the surface of
neutrophils and monocytes related with the causative type of infection. P values indicate statistically significant differences between sepsis
and severe sepsis/shock at the specific infection.
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regarding differences of MFI expression of TREM-1 on
neutrophils).
Differences similar to those found for the expression
of TREM-1 between sepsis and severe sepsis/shock were
not observed for sTREM-1 (Figure 4).
Discussion
TREM-1 is a receptor engaged on the cell membranes of
neutrophils and of monocytes that is expressed during
the septic syndrome upon stimulation with microbial
products. Activation of TREM-1 leads to the transcrip-
tion of genes of pro-inflammatory cytokines that play a
pivotal role in the amplification of the immune
response. During the septic process, surface TREM-1
expression on the cells of the innate immune system is
highly modulated [18-20]. Expression of TREM-1 on the
surface of circulating monocytes is increased in septic
shock as evidenced in a previous study of 25 patients.
Expression of TREM-1 was compared with patients with
systemic inflammatory response syndrome of non-infec-
tious origin and no data were available for patients at
the stages of sepsis and of severe sepsis [21]. It seems
that a circulating factor in the serum of shocked
patients stimulates the expression of TREM-1 [22].
Much more evidence is available for the kinetics of the
soluble counterpart of TREM-1 i.e. of sTREM-1. Con-
centrations are much greater in serum in the case of
septic shock than in the cases of sepsis or of severe sep-
sis [22-24]. To this end, many authors propose that
sTREM-1 may be used as a surrogate marker that helps
diagnosis of critically ill patients with signs of systemic
inflammatory response [25,26].
The present study provides further insight in the mod-
ulation of TREM-1 expression in sepsis. Results suggest
that TREM-1 expression on the membranes of neutro-
phils and monocytes in patients with septic syndrome is
related to the type of infection. Expression is decreased
Figure 2 Expression of TREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock on the surface of
neutrophils and monocytes in relation with the type of the pathogen. P values indicate statistically significant differences between sepsis
and severe sepsis/shock at the specific type of pathogen.
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from an intra-abdominal infection or from VAP/HAP
compared with patients at sepsis suffering from similar
infections. This is further decreased among patients at
septic shock. Modulation of the immune status in sepsis
by the underlying type of infection has also being shown
in a recent publication of our group. Both innate and
adaptive immune responses differed considerably
between sepsis due to VAP and sepsis due to other
types of infection. VAP was characterized by substantial
decreases of CD4-lymphocytes and immunoparalysis of
monocytes in contrast to other infections [27].
Modulation of the expression of TREM-1 was also
affected by the type of microbial pathogen. More pre-
cisely, expression of TREM-1 was decreased when
severe sepsis/shock developed in the field of infections
caused by Gram-negative community-acquired bacteria.
Expression of TREM-1 on the membranes of mono-
cytes is decreased in patients with severe sepsis/shock
and polymicrobial infections compared to patients with
sepsis. Explanations for these differences remain theore-
tical. The ligand of TREM-1 is not clearly defined.
TREM-1 receptor is mainly expressed on neutrophils
and monocytes after bacterial and fungal stimuli, so as
to be considered one important counterpart of the
innate immune response in sepsis [7,8]. The presented
data suggest that TREM-1 expression on neutrophils
and monocytes is decreased upon transition from sepsis
to severe sepsis/shock in a fashion depending on the
underlying type of infection and on the causative patho-
gen. Since TREM-1 is a pro-inflammatory receptor, it
may be hypothesized that the observed decrease of
TREM-1 expression upon aggravation to severe sepsis/
shock may be a component of the immunoparalysis tak-
ing place in sepsis. At the stage of immunoparalysis,
monocytes of septic patients fail to produce a similar
amount of cytokines as monocytes of the non-septic
host do when stimulated ex vivo [2].
Figure 3 Expression of TREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock on the surface of
neutrophils and monocytes in relation with the presence of infection of polymicrobial or monomicrobial origin. P values indicate
statistically significant differences between sepsis and severe sepsis/shock at the specific cause.
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cell membranes is shed in the systemic circulation in a
soluble form known as sTREM-1. sTREM-1 is consid-
ered to represent an anti-inflammatory response of the
host [28]. In the present study, serum kinetics of
sTREM-1 did not follow changes of the expression of
TREM-1 suggesting that simple shedding of the mem-
brane receptor did not take place.
Conclusions
The presented results show for the first time that
expression of the TREM-1 receptor on the cell mem-
branes of circulating neutrophils and monocytes early
after diagnosis differs greatly between sepsis and severe
sepsis/shock in relation; this is linked with the underly-
ing infection and the causative pathogen. These results
may have a major impact on therapeutics for the man-
agement of the septic patients.
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